US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
US4737456A
(en)
|
1985-05-09 |
1988-04-12 |
Syntex (U.S.A.) Inc. |
Reducing interference in ligand-receptor binding assays
|
US4676980A
(en)
|
1985-09-23 |
1987-06-30 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Target specific cross-linked heteroantibodies
|
US6548640B1
(en)
|
1986-03-27 |
2003-04-15 |
Btg International Limited |
Altered antibodies
|
IL85035A0
(en)
|
1987-01-08 |
1988-06-30 |
Int Genetic Eng |
Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
|
AU600575B2
(en)
|
1987-03-18 |
1990-08-16 |
Sb2, Inc. |
Altered antibodies
|
US5606040A
(en)
|
1987-10-30 |
1997-02-25 |
American Cyanamid Company |
Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
|
US5770701A
(en)
|
1987-10-30 |
1998-06-23 |
American Cyanamid Company |
Process for preparing targeted forms of methyltrithio antitumor agents
|
US5670373A
(en)
|
1988-01-22 |
1997-09-23 |
Kishimoto; Tadamitsu |
Antibody to human interleukin-6 receptor
|
US5126250A
(en)
|
1988-09-28 |
1992-06-30 |
Eli Lilly And Company |
Method for the reduction of heterogeneity of monoclonal antibodies
|
AU634186B2
(en)
|
1988-11-11 |
1993-02-18 |
Medical Research Council |
Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
|
DE3920358A1
(de)
|
1989-06-22 |
1991-01-17 |
Behringwerke Ag |
Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
|
US5208020A
(en)
|
1989-10-25 |
1993-05-04 |
Immunogen Inc. |
Cytotoxic agents comprising maytansinoids and their therapeutic use
|
CA2026147C
(en)
|
1989-10-25 |
2006-02-07 |
Ravi J. Chari |
Cytotoxic agents comprising maytansinoids and their therapeutic use
|
US5959177A
(en)
|
1989-10-27 |
1999-09-28 |
The Scripps Research Institute |
Transgenic plants expressing assembled secretory antibodies
|
US6150584A
(en)
|
1990-01-12 |
2000-11-21 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
US6075181A
(en)
|
1990-01-12 |
2000-06-13 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
US5770429A
(en)
|
1990-08-29 |
1998-06-23 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
EP0564531B1
(en)
|
1990-12-03 |
1998-03-25 |
Genentech, Inc. |
Enrichment method for variant proteins with altered binding properties
|
US5571894A
(en)
|
1991-02-05 |
1996-11-05 |
Ciba-Geigy Corporation |
Recombinant antibodies specific for a growth factor receptor
|
US5795965A
(en)
|
1991-04-25 |
1998-08-18 |
Chugai Seiyaku Kabushiki Kaisha |
Reshaped human to human interleukin-6 receptor
|
US6407213B1
(en)
|
1991-06-14 |
2002-06-18 |
Genentech, Inc. |
Method for making humanized antibodies
|
GB9114948D0
(en)
|
1991-07-11 |
1991-08-28 |
Pfizer Ltd |
Process for preparing sertraline intermediates
|
US6136310A
(en)
|
1991-07-25 |
2000-10-24 |
Idec Pharmaceuticals Corporation |
Recombinant anti-CD4 antibodies for human therapy
|
WO1993006217A1
(en)
|
1991-09-19 |
1993-04-01 |
Genentech, Inc. |
EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab')2 ANTIBODIES
|
US5587458A
(en)
|
1991-10-07 |
1996-12-24 |
Aronex Pharmaceuticals, Inc. |
Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
|
WO1993008829A1
(en)
|
1991-11-04 |
1993-05-13 |
The Regents Of The University Of California |
Compositions that mediate killing of hiv-infected cells
|
DE69333807T2
(de)
|
1992-02-06 |
2006-02-02 |
Chiron Corp., Emeryville |
Marker für krebs und biosynthetisches bindeprotein dafür
|
DK0669836T3
(da)
|
1992-11-13 |
1996-10-14 |
Idec Pharma Corp |
Terapeutisk anvendelse af kimære og radioaktivt mærkede antistoffer og humant B-lymfocytbegrænset differentieringsantigen til behandling af B-cellelymfom
|
US5635483A
(en)
|
1992-12-03 |
1997-06-03 |
Arizona Board Of Regents Acting On Behalf Of Arizona State University |
Tumor inhibiting tetrapeptide bearing modified phenethyl amides
|
US5780588A
(en)
|
1993-01-26 |
1998-07-14 |
Arizona Board Of Regents |
Elucidation and synthesis of selected pentapeptides
|
EP0714409A1
(en)
|
1993-06-16 |
1996-06-05 |
Celltech Therapeutics Limited |
Antibodies
|
US5773001A
(en)
|
1994-06-03 |
1998-06-30 |
American Cyanamid Company |
Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
|
US8017121B2
(en)
|
1994-06-30 |
2011-09-13 |
Chugai Seiyaku Kabushika Kaisha |
Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component
|
JP3865418B2
(ja)
|
1994-07-13 |
2007-01-10 |
中外製薬株式会社 |
ヒトインターロイキン−8に対する再構成ヒト抗体
|
WO1996002576A1
(fr)
|
1994-07-13 |
1996-02-01 |
Chugai Seiyaku Kabushiki Kaisha |
Anticorps humain reconstitue contre l'interleukine-8 humaine
|
US6048972A
(en)
|
1994-07-13 |
2000-04-11 |
Chugai Pharmaceutical Co., Ltd. |
Recombinant materials for producing humanized anti-IL-8 antibodies
|
TW416960B
(en)
|
1994-07-13 |
2001-01-01 |
Chugai Pharmaceutical Co Ltd |
Reshaped human antibody to human interleukin-8
|
CN1156460A
(zh)
|
1994-07-13 |
1997-08-06 |
中外制药株式会社 |
抗人白细胞介素-8的重构人抗体
|
RU2147442C1
(ru)
|
1994-10-21 |
2000-04-20 |
Кисимото Тадамицу |
Фармацевтическая композиция для профилактики или лечения заболеваний, вызываемых образованием il-6
|
US5789199A
(en)
|
1994-11-03 |
1998-08-04 |
Genentech, Inc. |
Process for bacterial production of polypeptides
|
US5731168A
(en)
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
US5840523A
(en)
|
1995-03-01 |
1998-11-24 |
Genetech, Inc. |
Methods and compositions for secretion of heterologous polypeptides
|
US5869046A
(en)
|
1995-04-14 |
1999-02-09 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
US5712374A
(en)
|
1995-06-07 |
1998-01-27 |
American Cyanamid Company |
Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
|
US5714586A
(en)
|
1995-06-07 |
1998-02-03 |
American Cyanamid Company |
Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
|
US6267958B1
(en)
|
1995-07-27 |
2001-07-31 |
Genentech, Inc. |
Protein formulation
|
GB9603256D0
(en)
|
1996-02-16 |
1996-04-17 |
Wellcome Found |
Antibodies
|
CA2262405A1
(en)
|
1996-08-02 |
1998-02-12 |
Bristol-Myers Squibb Company |
A method for inhibiting immunoglobulin-induced toxicity resulting from the use of immunoglobulins in therapy and in vivo diagnosis
|
US6025158A
(en)
|
1997-02-21 |
2000-02-15 |
Genentech, Inc. |
Nucleic acids encoding humanized anti-IL-8 monoclonal antibodies
|
US6171586B1
(en)
|
1997-06-13 |
2001-01-09 |
Genentech, Inc. |
Antibody formulation
|
CN1068524C
(zh)
|
1997-06-23 |
2001-07-18 |
叶庆炜 |
一种治疗顽症牛皮癣的药物
|
PT994903E
(pt)
|
1997-06-24 |
2005-10-31 |
Genentech Inc |
Metodos e composicoes para glicoproteinas galactosiladas
|
US6040498A
(en)
|
1998-08-11 |
2000-03-21 |
North Caroline State University |
Genetically engineered duckweed
|
US20020187150A1
(en)
|
1997-08-15 |
2002-12-12 |
Chugai Seiyaku Kabushiki Kaisha |
Preventive and/or therapeutic agent for systemic lupus erythematosus comprising anti-IL-6 receptor antibody as an active ingredient
|
WO1999022764A1
(en)
|
1997-10-31 |
1999-05-14 |
Genentech, Inc. |
Methods and compositions comprising glycoprotein glycoforms
|
US6610833B1
(en)
|
1997-11-24 |
2003-08-26 |
The Institute For Human Genetics And Biochemistry |
Monoclonal human natural antibodies
|
IL136544A0
(en)
|
1997-12-05 |
2001-06-14 |
Scripps Research Inst |
Humanization of murine antibody
|
US6458355B1
(en)
|
1998-01-22 |
2002-10-01 |
Genentech, Inc. |
Methods of treating inflammatory disease with anti-IL-8 antibody fragment-polymer conjugates
|
DE69937994T2
(de)
|
1998-03-17 |
2008-12-24 |
Chugai Seiyaku K.K. |
Prophylaktische oder therapeutische mittel gegen entzündliche erkrankungen des verdauungstraktes enthaltend antagonistische il-6 rezeptor antikörper
|
US6194551B1
(en)
|
1998-04-02 |
2001-02-27 |
Genentech, Inc. |
Polypeptide variants
|
ES2532910T3
(es)
|
1998-04-02 |
2015-04-01 |
Genentech, Inc. |
Variantes de anticuerpos y fragmentos de los mismos
|
WO1999054342A1
(en)
|
1998-04-20 |
1999-10-28 |
Pablo Umana |
Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
|
GB9809951D0
(en)
|
1998-05-08 |
1998-07-08 |
Univ Cambridge Tech |
Binding molecules
|
US6737056B1
(en)
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
ES2694002T3
(es)
|
1999-01-15 |
2018-12-17 |
Genentech, Inc. |
Polipéptido que comprende una región Fc de IgG1 humana variante
|
AU2006225302B2
(en)
|
1999-03-25 |
2010-08-12 |
AbbVie Deutschland GmbH & Co. KG |
Human antibodies that bind human IL-12 and methods for producing
|
ES2568899T3
(es)
|
1999-04-09 |
2016-05-05 |
Kyowa Hakko Kirin Co., Ltd. |
Procedimiento para controlar la actividad de una molécula inmunofuncional
|
SK782002A3
(en)
|
1999-07-21 |
2003-08-05 |
Lexigen Pharm Corp |
FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
|
US7125978B1
(en)
|
1999-10-04 |
2006-10-24 |
Medicago Inc. |
Promoter for regulating expression of foreign genes
|
AU782626B2
(en)
|
1999-10-04 |
2005-08-18 |
Medicago Inc. |
Method for regulating transcription of foreign genes
|
JP4668498B2
(ja)
|
1999-10-19 |
2011-04-13 |
協和発酵キリン株式会社 |
ポリペプチドの製造方法
|
AU784983B2
(en)
|
1999-12-15 |
2006-08-17 |
Genentech Inc. |
Shotgun scanning, a combinatorial method for mapping functional protein epitopes
|
ES2274823T3
(es)
|
1999-12-29 |
2007-06-01 |
Immunogen, Inc. |
Agentes cototoxicos que comprenden doxorrubicinas y daunorrubicinas y su utilizacion terapeutica.
|
PL357939A1
(en)
|
2000-04-11 |
2004-08-09 |
Genentech, Inc. |
Multivalent antibodies and uses therefor
|
US7064191B2
(en)
|
2000-10-06 |
2006-06-20 |
Kyowa Hakko Kogyo Co., Ltd. |
Process for purifying antibody
|
US6946292B2
(en)
|
2000-10-06 |
2005-09-20 |
Kyowa Hakko Kogyo Co., Ltd. |
Cells producing antibody compositions with increased antibody dependent cytotoxic activity
|
ES2651952T3
(es)
|
2000-10-06 |
2018-01-30 |
Kyowa Hakko Kirin Co., Ltd. |
Células que producen unas composiciones de anticuerpo
|
AU2000279625A1
(en)
|
2000-10-27 |
2002-05-15 |
Chugai Seiyaku Kabushiki Kaisha |
Blood mmp-3 level-lowering agent containing il-6 antgonist as the active ingredient
|
US6596541B2
(en)
|
2000-10-31 |
2003-07-22 |
Regeneron Pharmaceuticals, Inc. |
Methods of modifying eukaryotic cells
|
CA2430013C
(en)
|
2000-11-30 |
2011-11-22 |
Medarex, Inc. |
Transgenic transchromosomal rodents for making human antibodies
|
PT1355919E
(pt)
|
2000-12-12 |
2011-03-02 |
Medimmune Llc |
Moléculas com semivida longa, composições que as contêm e suas utilizações
|
DK1366067T3
(da)
|
2001-03-07 |
2012-10-22 |
Merck Patent Gmbh |
Ekspressionsteknologi for proteiner indeholdende en hybrid isotype-antistof-enhed
|
UA80091C2
(en)
|
2001-04-02 |
2007-08-27 |
Chugai Pharmaceutical Co Ltd |
Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist
|
AU2002258778C1
(en)
|
2001-04-13 |
2008-12-04 |
Biogen Ma Inc. |
Antibodies to VLA-1
|
HUP0700103A3
(en)
|
2001-08-03 |
2012-09-28 |
Glycart Biotechnology Ag |
Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
|
CN100423777C
(zh)
|
2001-10-25 |
2008-10-08 |
杰南技术公司 |
糖蛋白组合物
|
ATE395413T1
(de)
|
2001-12-03 |
2008-05-15 |
Amgen Fremont Inc |
Antikörperkategorisierung auf der grundlage von bindungseigenschaften
|
US20040093621A1
(en)
|
2001-12-25 |
2004-05-13 |
Kyowa Hakko Kogyo Co., Ltd |
Antibody composition which specifically binds to CD20
|
US20040132101A1
(en)
|
2002-09-27 |
2004-07-08 |
Xencor |
Optimized Fc variants and methods for their generation
|
US7657380B2
(en)
|
2003-12-04 |
2010-02-02 |
Xencor, Inc. |
Methods of generating variant antibodies with increased host string content
|
AU2003217912A1
(en)
|
2002-03-01 |
2003-09-16 |
Xencor |
Antibody optimization
|
WO2003085118A1
(fr)
|
2002-04-09 |
2003-10-16 |
Kyowa Hakko Kogyo Co., Ltd. |
Procede de production de composition anticorps
|
JPWO2003084569A1
(ja)
|
2002-04-09 |
2005-08-11 |
協和醗酵工業株式会社 |
抗体組成物含有医薬
|
EP1498491A4
(en)
|
2002-04-09 |
2006-12-13 |
Kyowa Hakko Kogyo Kk |
METHOD FOR INCREASING THE ACTIVITY OF AN ANTIBODY COMPOSITION FOR BINDING TO THE FC GAMMA RECEPTOR IIIA
|
AU2003236020B2
(en)
|
2002-04-09 |
2009-03-19 |
Kyowa Hakko Kirin Co., Ltd. |
Cell with depression or deletion of the activity of protein participating in GDP-fucose transport
|
CN1930288B
(zh)
|
2002-04-09 |
2012-08-08 |
协和发酵麒麟株式会社 |
基因组被修饰的细胞
|
US20050031613A1
(en)
|
2002-04-09 |
2005-02-10 |
Kazuyasu Nakamura |
Therapeutic agent for patients having human FcgammaRIIIa
|
DK1495055T3
(da)
|
2002-04-18 |
2013-11-11 |
Genencor Int |
Produktion af funktionelle antistoffer i filamentøse svampe
|
WO2005056606A2
(en)
|
2003-12-03 |
2005-06-23 |
Xencor, Inc |
Optimized antibodies that target the epidermal growth factor receptor
|
JP4468803B2
(ja)
|
2002-05-31 |
2010-05-26 |
ジーイー・ヘルスケア・バイオ−サイエンシーズ・アーベー |
結合剤を基板表面にカップリングさせる方法
|
JP4753578B2
(ja)
|
2002-06-03 |
2011-08-24 |
ジェネンテック, インコーポレイテッド |
合成抗体ファージライブラリー
|
KR100960560B1
(ko)
|
2002-09-27 |
2010-06-03 |
젠코어 인코포레이티드 |
최적화된 Fc 변이체 및 그의 제조 방법
|
US7217797B2
(en)
|
2002-10-15 |
2007-05-15 |
Pdl Biopharma, Inc. |
Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
|
US7361740B2
(en)
|
2002-10-15 |
2008-04-22 |
Pdl Biopharma, Inc. |
Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
|
SI1562972T1
(sl)
|
2002-10-15 |
2010-12-31 |
Facet Biotech Corp |
ALTERACIJA FcRn VEZANIH AFINITET ALI SERUMSKIH RAZPOLOVNIH DOB ANTITELESC Z MUTAGENEZO
|
US7217798B2
(en)
|
2003-10-15 |
2007-05-15 |
Pdl Biopharma, Inc. |
Alteration of Fc-fusion protein serum half-lives by mutagenesis
|
EP1944320A1
(en)
|
2002-12-16 |
2008-07-16 |
Genentech, Inc. |
Immunoglobulin variants and uses thereof
|
ES2373947T3
(es)
|
2002-12-16 |
2012-02-10 |
Genmab A/S |
Anticuerpos monoclonales humanos contra interleucina 8 (il-8).
|
CA2921578C
(en)
|
2002-12-24 |
2017-02-14 |
Rinat Neuroscience Corp. |
Anti-ngf antibodies and methods using same
|
CA2510003A1
(en)
|
2003-01-16 |
2004-08-05 |
Genentech, Inc. |
Synthetic antibody phage libraries
|
US20060104968A1
(en)
|
2003-03-05 |
2006-05-18 |
Halozyme, Inc. |
Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
|
US7871607B2
(en)
|
2003-03-05 |
2011-01-18 |
Halozyme, Inc. |
Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
|
GB2401040A
(en)
|
2003-04-28 |
2004-11-03 |
Chugai Pharmaceutical Co Ltd |
Method for treating interleukin-6 related diseases
|
EP1636264A2
(en)
|
2003-06-24 |
2006-03-22 |
MERCK PATENT GmbH |
Tumour necrosis factor receptor molecules with reduced immunogenicity
|
US20050033029A1
(en)
|
2003-06-30 |
2005-02-10 |
Jin Lu |
Engineered anti-target immunoglobulin derived proteins, compositions, methods and uses
|
AU2004279742A1
(en)
|
2003-10-08 |
2005-04-21 |
Kyowa Hakko Kirin Co., Ltd. |
Fused protein composition
|
JPWO2005035778A1
(ja)
|
2003-10-09 |
2006-12-21 |
協和醗酵工業株式会社 |
α1,6−フコシルトランスフェラーゼの機能を抑制するRNAを用いた抗体組成物の製造法
|
HUE038955T2
(hu)
|
2003-11-05 |
2018-12-28 |
Roche Glycart Ag |
Antigén-kötõ molekulák fokozott Fc receptor-kötõ affinitással és effektor funkcióval
|
SG10201701737XA
(en)
|
2003-11-06 |
2017-04-27 |
Seattle Genetics Inc |
Monomethylvaline compounds capable of conjugation to ligands
|
US20050100965A1
(en)
|
2003-11-12 |
2005-05-12 |
Tariq Ghayur |
IL-18 binding proteins
|
EP2385069A3
(en)
|
2003-11-12 |
2012-05-30 |
Biogen Idec MA Inc. |
Neonatal Fc rReceptor (FcRn)- binding polypeptide variants, dimeric Fc binding proteins and methods related thereto
|
WO2005053742A1
(ja)
|
2003-12-04 |
2005-06-16 |
Kyowa Hakko Kogyo Co., Ltd. |
抗体組成物を含有する医薬
|
AR048210A1
(es)
|
2003-12-19 |
2006-04-12 |
Chugai Pharmaceutical Co Ltd |
Un agente preventivo para la vasculitis.
|
EP1697520A2
(en)
|
2003-12-22 |
2006-09-06 |
Xencor, Inc. |
Fc polypeptides with novel fc ligand binding sites
|
WO2005092925A2
(en)
|
2004-03-24 |
2005-10-06 |
Xencor, Inc. |
Immunoglobulin variants outside the fc region
|
AR048335A1
(es)
|
2004-03-24 |
2006-04-19 |
Chugai Pharmaceutical Co Ltd |
Agentes terapeuticos para trastornos del oido interno que contienen un antagonista de il- 6 como un ingrediente activo
|
MXPA06011199A
(es)
|
2004-03-31 |
2007-04-16 |
Genentech Inc |
Anticuerpos anti-tgf-beta humanizados.
|
US7785903B2
(en)
|
2004-04-09 |
2010-08-31 |
Genentech, Inc. |
Variable domain library and uses
|
WO2005123780A2
(en)
|
2004-04-09 |
2005-12-29 |
Protein Design Labs, Inc. |
Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis
|
SG172616A1
(en)
|
2004-04-13 |
2011-07-28 |
Hoffmann La Roche |
Anti-p-selectin antibodies
|
AU2005259992A1
(en)
|
2004-06-25 |
2006-01-12 |
Medimmune, Llc |
Increasing the production of recombinant antibodies in mammalian cells by site-directed mutagenesis
|
WO2006085967A2
(en)
|
2004-07-09 |
2006-08-17 |
Xencor, Inc. |
OPTIMIZED ANTI-CD20 MONOCONAL ANTIBODIES HAVING Fc VARIANTS
|
WO2006019447A1
(en)
|
2004-07-15 |
2006-02-23 |
Xencor, Inc. |
Optimized fc variants
|
WO2006020114A2
(en)
|
2004-08-04 |
2006-02-23 |
Applied Molecular Evolution, Inc. |
Variant fc regions
|
WO2006031370A2
(en)
|
2004-08-19 |
2006-03-23 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
TWI380996B
(zh)
|
2004-09-17 |
2013-01-01 |
Hoffmann La Roche |
抗ox40l抗體
|
ES2579805T3
(es)
|
2004-09-23 |
2016-08-16 |
Genentech, Inc. |
Anticuerpos y conjugados modificados por ingeniería genética con cisteína
|
JO3000B1
(ar)
|
2004-10-20 |
2016-09-05 |
Genentech Inc |
مركبات أجسام مضادة .
|
WO2006047350A2
(en)
|
2004-10-21 |
2006-05-04 |
Xencor, Inc. |
IgG IMMUNOGLOBULIN VARIANTS WITH OPTIMIZED EFFECTOR FUNCTION
|
SG156672A1
(en)
|
2004-10-22 |
2009-11-26 |
Amgen Inc |
Methods for refolding of recombinant antibodies
|
WO2006050166A2
(en)
|
2004-10-29 |
2006-05-11 |
Medimmune, Inc. |
Methods of preventing and treating rsv infections and related conditions
|
US7632497B2
(en)
|
2004-11-10 |
2009-12-15 |
Macrogenics, Inc. |
Engineering Fc Antibody regions to confer effector function
|
US8802820B2
(en)
|
2004-11-12 |
2014-08-12 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
EP2332985A3
(en)
|
2004-11-12 |
2012-01-25 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
CA2592015A1
(en)
|
2004-12-27 |
2006-07-06 |
Progenics Pharmaceuticals (Nevada), Inc. |
Orally deliverable and anti-toxin antibodies and methods for making and using them
|
PT1772465E
(pt)
|
2005-01-05 |
2009-05-21 |
F Star Biotech Forsch & Entw |
Domínios de imunoglobulina sintética com propriedades de ligação construídos em regiões da molécula diferentes das regiões determinantes de complementaridade
|
WO2006076594A2
(en)
|
2005-01-12 |
2006-07-20 |
Xencor, Inc. |
Antibodies and fc fusion proteins with altered immunogenicity
|
WO2006075668A1
(ja)
|
2005-01-12 |
2006-07-20 |
Kirin Beer Kabushiki Kaisha |
安定化されたヒトIgG2およびIgG3抗体
|
US7700099B2
(en)
|
2005-02-14 |
2010-04-20 |
Merck & Co., Inc. |
Non-immunostimulatory antibody and compositions containing the same
|
CA2602663A1
(en)
|
2005-03-31 |
2006-10-05 |
Xencor, Inc. |
Fc variants with optimized properties
|
AU2006236417B2
(en)
|
2005-04-20 |
2011-02-03 |
Amgen Fremont Inc. |
High affinity fully human monoclonal antibodies to interleukin-8 and epitopes for such antibodies
|
US8163881B2
(en)
|
2005-05-31 |
2012-04-24 |
The Board Of Regents Of The University Of Texas System |
Immunoglobulin molecules with improved characteristics
|
US7557190B2
(en)
|
2005-07-08 |
2009-07-07 |
Xencor, Inc. |
Optimized proteins that target Ep-CAM
|
SI1919503T1
(sl)
|
2005-08-10 |
2015-02-27 |
Macrogenics, Inc. |
Identifikacija in inĺ˝eniring protiteles z variantnimi fc regijami in postopki za njih uporabo
|
CU23578A1
(es)
*
|
2005-09-16 |
2010-09-30 |
Ct Ingenieria Genetica Biotech |
Proteína de la cápsida del virus dengue inductora de respuesta protectora y composición vacunal
|
AU2006297173A1
(en)
|
2005-09-29 |
2007-04-12 |
Viral Logic Systems Technology Corp. |
Immunomodulatory compositions and uses therefor
|
EP1931709B1
(en)
|
2005-10-03 |
2016-12-07 |
Xencor, Inc. |
Fc variants with optimized fc receptor binding properties
|
CA2625998C
(en)
|
2005-10-06 |
2015-12-01 |
Xencor, Inc. |
Optimized anti-cd30 antibodies
|
EP1941907B1
(en)
|
2005-10-14 |
2016-03-23 |
Fukuoka University |
Inhibitor of transplanted islet dysfunction in islet transplantation
|
KR101239051B1
(ko)
|
2005-10-21 |
2013-03-04 |
추가이 세이야쿠 가부시키가이샤 |
심장질환 치료제
|
WO2007056441A2
(en)
|
2005-11-07 |
2007-05-18 |
Genentech, Inc. |
Binding polypeptides with diversified and consensus vh/vl hypervariable sequences
|
CU23586A1
(es)
*
|
2005-11-22 |
2010-10-30 |
Ct Ingenieria Genetica Biotech |
Métodos y proteínas para el tratamiento profiláctico y/o terapéutico de los cuatro serotipos del virus de dengue y otros flavivirus
|
EP1973951A2
(en)
|
2005-12-02 |
2008-10-01 |
Genentech, Inc. |
Binding polypeptides with restricted diversity sequences
|
US20080071063A1
(en)
|
2006-02-03 |
2008-03-20 |
Medimmune, Inc. |
Protein Formulations
|
JP5374359B2
(ja)
|
2006-03-17 |
2013-12-25 |
バイオジェン・アイデック・エムエイ・インコーポレイテッド |
安定化されたポリペプチド化合物
|
EP2006380A4
(en)
|
2006-03-23 |
2010-08-11 |
Kyowa Hakko Kirin Co Ltd |
AGONIST ANTIBODY AGAINST THE HUMAN THROMBOPOIETINE RECEPTOR
|
EA200802061A1
(ru)
|
2006-03-28 |
2009-04-28 |
Байоджен Айдек Эмэй Инк. |
Антитело или его фрагмент, специфично связывающееся с рецептором 1 инсулиноподобного фактора роста (igf-r1) (варианты), композиция на его основе, полинуклеотид, кодирующий вариабельную область антитела (варианты), содержащие полинуклеотид композиция (варианты) и вектор, содержащая вектор клетка-хозяин (варианты), способ продуцирования антитела или его фрагмента (варианты) и способ лечения гиперпролиферативного заболевания у животного организма
|
JP5624276B2
(ja)
|
2006-03-31 |
2014-11-12 |
中外製薬株式会社 |
抗体の血中動態を制御する方法
|
EP3345616A1
(en)
|
2006-03-31 |
2018-07-11 |
Chugai Seiyaku Kabushiki Kaisha |
Antibody modification method for purifying bispecific antibody
|
CA2648644C
(en)
|
2006-04-07 |
2016-01-05 |
Osaka University |
Muscle regeneration promoter
|
CA2651567A1
(en)
|
2006-05-09 |
2007-11-22 |
Genentech, Inc. |
Binding polypeptides with optimized scaffolds
|
CL2007001829A1
(es)
|
2006-06-23 |
2008-01-25 |
Smithkline Beecham Corp |
P-toluensulfonato de n-[4-cloro-2-hidroxi-3-(piperazina-1-sulfonil)fenil]-n-(2-cloro-3-fluorofenil)urea;procedimiento de preparacion;composicion farmaceutica;combinacion farmaceutica;y uso en el tratamiento de una enfermedad mediada por la quiimioquina il-8, tales como asma y epoc.
|
AR062223A1
(es)
|
2006-08-09 |
2008-10-22 |
Glycart Biotechnology Ag |
Moleculas de adhesion al antigeno que se adhieren a egfr, vectores que los codifican, y sus usos de estas
|
WO2008022152A2
(en)
|
2006-08-14 |
2008-02-21 |
Xencor, Inc. |
Optimized antibodies that target cd19
|
EP2471816A1
(en)
|
2006-08-30 |
2012-07-04 |
Genentech, Inc. |
Multispecific antibodies
|
ATE551071T1
(de)
|
2006-09-08 |
2012-04-15 |
Medimmune Llc |
Humanisierte anti-cd19-antikörper und ihre verwendung für die behandlung von krebs, transplantationen und autoimmunerkrankungen
|
AU2007299843B2
(en)
|
2006-09-18 |
2012-03-08 |
Xencor, Inc |
Optimized antibodies that target HM1.24
|
WO2008121160A2
(en)
|
2006-11-21 |
2008-10-09 |
Xencor, Inc. |
Optimized antibodies that target cd5
|
CN100455598C
(zh)
|
2006-11-29 |
2009-01-28 |
中国抗体制药有限公司 |
功能人源化抗人cd20抗体及其应用
|
US20080226635A1
(en)
|
2006-12-22 |
2008-09-18 |
Hans Koll |
Antibodies against insulin-like growth factor I receptor and uses thereof
|
WO2008091798A2
(en)
|
2007-01-22 |
2008-07-31 |
Xencor, Inc. |
Optimized ca9 antibodies and methods of using the same
|
AU2008207898B2
(en)
|
2007-01-23 |
2012-05-03 |
Xencor, Inc |
Optimized CD40 antibodies and methods of using the same
|
WO2008092117A2
(en)
|
2007-01-25 |
2008-07-31 |
Xencor, Inc. |
Immunoglobulins with modifications in the fcr binding region
|
WO2008098115A2
(en)
|
2007-02-07 |
2008-08-14 |
Xencor, Inc. |
Optimized igf-1r antibodies and methods of using the same
|
US8337854B2
(en)
*
|
2007-04-04 |
2012-12-25 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Monoclonal antibodies against dengue and other viruses with deletion in Fc region
|
CL2008001071A1
(es)
|
2007-04-17 |
2009-05-22 |
Smithkline Beecham Corp |
Metodo para obtener anticuerpo penta-especifico contra il-8/cxcl8, gro-alfa/cxcl1, gro-beta/cxcl2), gro-gama/cxcl3 y ena-78/cxcl5 humanas; anticuerpo penta-especifico; proceso de produccion del mismo; vector, hbridoma o celela que lo comprende; composicion farmceutica; uso para tratar copd, otras enfermedades.
|
CN100592373C
(zh)
|
2007-05-25 |
2010-02-24 |
群康科技(深圳)有限公司 |
液晶显示面板驱动装置及其驱动方法
|
EP3392273A1
(en)
|
2007-05-30 |
2018-10-24 |
Xencor, Inc. |
Methods and compositions for inhibiting cd32b expressing cells
|
WO2008145141A1
(en)
|
2007-05-31 |
2008-12-04 |
Genmab A/S |
Method for extending the half-life of exogenous or endogenous soluble molecules
|
DK2164961T3
(en)
|
2007-06-25 |
2015-03-02 |
Esbatech Alcon Biomed Res Unit |
Sequence based forward position and optimization of single chain antibodies
|
CA2689941C
(en)
|
2007-06-25 |
2019-10-29 |
Esbatech Ag |
Methods of modifying antibodies, and modified antibodies with improved functional properties
|
US20110105724A1
(en)
|
2007-08-16 |
2011-05-05 |
Stephanie Jane Clegg |
Novel compounds
|
EP2197490A2
(en)
|
2007-08-28 |
2010-06-23 |
Biogen Idec MA, Inc. |
Compositions that bind multiple epitopes of igf-1r
|
JP2010537985A
(ja)
|
2007-08-28 |
2010-12-09 |
バイオジェン アイデック マサチューセッツ インコーポレイテッド |
抗igf−1r抗体およびその使用
|
EP2031064A1
(de)
|
2007-08-29 |
2009-03-04 |
Boehringer Ingelheim Pharma GmbH & Co. KG |
Verfahren zur Steigerung von Proteintitern
|
MX2010002683A
(es)
|
2007-09-14 |
2010-03-26 |
Amgen Inc |
Poblaciones de anticuerpos homogeneos.
|
PE20140132A1
(es)
|
2007-09-26 |
2014-02-14 |
Chugai Pharmaceutical Co Ltd |
Anticuerpo anti-receptor de il-6
|
KR102225009B1
(ko)
|
2007-09-26 |
2021-03-08 |
추가이 세이야쿠 가부시키가이샤 |
항체 정상영역 개변체
|
JP5334319B2
(ja)
|
2007-09-26 |
2013-11-06 |
中外製薬株式会社 |
Cdrのアミノ酸置換により抗体の等電点を改変する方法
|
JO3076B1
(ar)
|
2007-10-17 |
2017-03-15 |
Janssen Alzheimer Immunotherap |
نظم العلاج المناعي المعتمد على حالة apoe
|
BRPI0821110B8
(pt)
|
2007-12-05 |
2021-05-25 |
Chugai Pharmaceutical Co Ltd |
anticorpo de neutralização de anti-nr10/il31ra, composição farmacêutica compreendendo o referido anticorpo e uso do mesmo
|
SI2235059T1
(sl)
|
2007-12-26 |
2015-06-30 |
Xencor, Inc. |
Fc variante s spremenjeno vezjo na fcrn
|
PL2235064T3
(pl)
|
2008-01-07 |
2016-06-30 |
Amgen Inc |
Sposób otrzymywania cząsteczek przeciwciał z heterodimerycznymi fc z zastosowaniem kierujących efektów elektrostatycznych
|
JP5608100B2
(ja)
|
2008-02-08 |
2014-10-15 |
メディミューン,エルエルシー |
低下したFcリガンド親和性を有する抗IFNAR1抗体
|
CN101343319B
(zh)
*
|
2008-04-10 |
2012-05-09 |
中国人民解放军第三军医大学 |
抗登革病毒e蛋白的单克隆抗体、制备方法及其应用
|
KR20220162801A
(ko)
|
2008-04-11 |
2022-12-08 |
추가이 세이야쿠 가부시키가이샤 |
복수 분자의 항원에 반복 결합하는 항원 결합 분자
|
ES2742419T3
(es)
|
2008-09-17 |
2020-02-14 |
Xencor Inc |
Nuevas composiciones y métodos para tratar trastornos mediados por IgE
|
WO2010043977A2
(en)
*
|
2008-10-13 |
2010-04-22 |
Institute For Research In Biomedicine |
Dengue virus neutralizing antibodies and uses thereof
|
AU2009303526B2
(en)
|
2008-10-14 |
2015-01-15 |
Genentech, Inc. |
Immunoglobulin variants and uses thereof
|
EP2409990A4
(en)
|
2009-03-19 |
2013-01-23 |
Chugai Pharmaceutical Co Ltd |
VARIANT OF A CONSTANT ANTIBODY REGION
|
EP2409991B1
(en)
|
2009-03-19 |
2017-05-03 |
Chugai Seiyaku Kabushiki Kaisha |
Antibody constant region variant
|
EP2233500A1
(en)
|
2009-03-20 |
2010-09-29 |
LFB Biotechnologies |
Optimized Fc variants
|
GB0914691D0
(en)
|
2009-08-21 |
2009-09-30 |
Lonza Biologics Plc |
Immunoglobulin variants
|
US10150808B2
(en)
|
2009-09-24 |
2018-12-11 |
Chugai Seiyaku Kabushiki Kaisha |
Modified antibody constant regions
|
US8362210B2
(en)
|
2010-01-19 |
2013-01-29 |
Xencor, Inc. |
Antibody variants with enhanced complement activity
|
US20120315267A1
(en)
|
2010-02-09 |
2012-12-13 |
Glaxosmithkline Llc |
Novel uses
|
EP2543730B1
(en)
|
2010-03-04 |
2018-10-31 |
Chugai Seiyaku Kabushiki Kaisha |
Antibody constant region variant
|
TWI667257B
(zh)
|
2010-03-30 |
2019-08-01 |
中外製藥股份有限公司 |
促進抗原消失之具有經修飾的FcRn親和力之抗體
|
AU2011283694B2
(en)
|
2010-07-29 |
2017-04-13 |
Xencor, Inc. |
Antibodies with modified isoelectric points
|
EP2647706B1
(en)
|
2010-11-30 |
2023-05-17 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
|
EA201390874A1
(ru)
*
|
2010-12-14 |
2013-12-30 |
Нэшнл Юниверсити Оф Сингапур |
Моноклональное антитело человека со специфичностью к белку e вируса денге серотипа 1 и его применение
|
JP6043629B2
(ja)
|
2011-01-07 |
2016-12-14 |
中外製薬株式会社 |
抗体の物性を改善させる方法
|
WO2012132067A1
(ja)
|
2011-03-30 |
2012-10-04 |
中外製薬株式会社 |
抗原結合分子の血漿中滞留性と免疫原性を改変する方法
|
EP2679681B2
(en)
|
2011-02-25 |
2023-11-15 |
Chugai Seiyaku Kabushiki Kaisha |
FcgammaRIIB-specific FC antibody
|
KR101641057B1
(ko)
|
2011-05-04 |
2016-07-20 |
오메로스 코포레이션 |
Masp-2 의존적 보체 활성화를 억제하는 조성물
|
US9738707B2
(en)
|
2011-07-15 |
2017-08-22 |
Biogen Ma Inc. |
Heterodimeric Fc regions, binding molecules comprising same, and methods relating thereto
|
US20140335089A1
(en)
|
2011-09-30 |
2014-11-13 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule for promoting elimination of antigens
|
TW201817744A
(zh)
|
2011-09-30 |
2018-05-16 |
日商中外製藥股份有限公司 |
具有促進抗原清除之FcRn結合域的治療性抗原結合分子
|
RU2732151C2
(ru)
|
2011-09-30 |
2020-09-11 |
Чугаи Сейяку Кабусики Кайся |
Библиотека зависимых от концентрации ионов связывающих молекул
|
WO2013081143A1
(ja)
|
2011-11-30 |
2013-06-06 |
中外製薬株式会社 |
免疫複合体を形成する細胞内への運搬体(キャリア)を含む医薬
|
WO2013089647A1
(en)
*
|
2011-12-16 |
2013-06-20 |
Agency For Science, Technology And Research |
Binding molecules against dengue virus and uses thereof
|
CN107266564A
(zh)
|
2012-02-24 |
2017-10-20 |
中外制药株式会社 |
经由FcγIIB促进抗原消除的抗原结合分子
|
US9821050B2
(en)
|
2012-04-02 |
2017-11-21 |
The University Of North Carolina At Chapel Hill |
Chimeric dengue virus E glycoproteins comprising mutant domain I and domain II hinge regions
|
WO2013166099A1
(en)
|
2012-05-01 |
2013-11-07 |
Glaxosmithkline Llc |
Novel antibodies
|
WO2013173348A1
(en)
*
|
2012-05-14 |
2013-11-21 |
The Usa, As Represented By The Secretary, Dept. Of Health & Human Services |
Cross-reactive antibodies against dengue virus and uses thereof
|
DK2857419T3
(da)
|
2012-05-30 |
2021-03-29 |
Chugai Pharmaceutical Co Ltd |
Antigen-bindende molekyle til eliminering af aggregerede antigener
|
CA2874721A1
(en)
|
2012-05-30 |
2013-12-05 |
Tomoyuki Igawa |
Target tissue-specific antigen-binding molecule
|
EP2869845B1
(en)
|
2012-07-06 |
2019-08-28 |
Genmab B.V. |
Dimeric protein with triple mutations
|
KR102165384B1
(ko)
|
2012-08-07 |
2020-10-16 |
메사추세츠 인스티튜트 오브 테크놀로지 |
항-뎅기 바이러스 항체 및 이들의 용도
|
BR112015001955A2
(pt)
|
2012-08-24 |
2017-11-07 |
Chugai Pharmaceutical Co Ltd |
variante de região fc específica de fcgamariib
|
US9701759B2
(en)
|
2013-01-14 |
2017-07-11 |
Xencor, Inc. |
Heterodimeric proteins
|
BR112015017619A2
(pt)
|
2013-01-24 |
2017-11-21 |
Glaxosmithkline Ip Dev Ltd |
formulação líquida, uso de uma formulação, e, kit
|
US10858417B2
(en)
|
2013-03-15 |
2020-12-08 |
Xencor, Inc. |
Heterodimeric proteins
|
WO2014145159A2
(en)
|
2013-03-15 |
2014-09-18 |
Permeon Biologics, Inc. |
Charge-engineered antibodies or compositions of penetration-enhanced targeting proteins and methods of use
|
KR102561553B1
(ko)
|
2013-03-15 |
2023-07-31 |
젠코어 인코포레이티드 |
이형이량체 단백질
|
WO2014163101A1
(ja)
*
|
2013-04-02 |
2014-10-09 |
中外製薬株式会社 |
Fc領域改変体
|
CA2911600A1
(en)
|
2013-05-17 |
2014-11-20 |
Centre National De La Recherche Scientifique (Cnrs) |
Anti-cxcl1, cxcl7 and cxcl8 antibodies and their applications
|
DK3004174T3
(da)
|
2013-05-31 |
2019-07-22 |
Zymeworks Inc |
Heteromultimerer med reduceret eller nedreguleret effektorfunktion
|
CN105829341A
(zh)
*
|
2013-12-13 |
2016-08-03 |
宾夕法尼亚大学理事会 |
Dna抗体构建体及其使用方法
|
KR102356951B1
(ko)
|
2014-02-11 |
2022-01-27 |
비스테라, 인크. |
뎅기열 바이러스에 대한 항체 분자 및 그의 용도
|
WO2015123362A1
(en)
|
2014-02-11 |
2015-08-20 |
Massachusetts Institute Of Technology |
Novel full spectrum anti-dengue antibody
|
GB201413086D0
(en)
|
2014-07-23 |
2014-09-03 |
Imp Innovations Ltd And Inst Pasteur |
Methods
|
KR20180054923A
(ko)
*
|
2014-12-19 |
2018-05-24 |
추가이 세이야쿠 가부시키가이샤 |
항-마이오스타틴 항체, 변이체 Fc 영역을 함유하는 폴리펩타이드, 및 사용 방법
|
MX2017008978A
(es)
|
2015-02-05 |
2017-10-25 |
Chugai Pharmaceutical Co Ltd |
Anticuerpos que comprenden un dominio de union al antigeno dependiente de la concentracion ionica, variantes de la region fc, antiocuerpor de union a interleucina 8 (il-8) y usos de los mismos.
|
WO2016130516A1
(en)
|
2015-02-09 |
2016-08-18 |
Research Development Foundation |
Engineered immunoglobulin fc polypeptides displaying improved complement activation
|
US10316078B2
(en)
*
|
2015-03-17 |
2019-06-11 |
Agency For Science, Technology And Research |
Serotype cross-reactive, dengue neutralizing antibody and uses thereof
|
US10940126B2
(en)
|
2015-07-03 |
2021-03-09 |
Camilla Svensson |
Inhibition of IL-8 in the treatment of pain and/or bone loss
|
KR20230079500A
(ko)
|
2015-09-18 |
2023-06-07 |
추가이 세이야쿠 가부시키가이샤 |
Il-8에 결합하는 항체 및 그의 사용
|
GB201610162D0
(en)
|
2016-06-10 |
2016-07-27 |
Imp Innovations Ltd And Inst Pasteur |
Methods
|
TW201815821A
(zh)
|
2016-07-18 |
2018-05-01 |
美商再生元醫藥公司 |
抗茲卡病毒抗體及使用方法
|
US11053308B2
(en)
|
2016-08-05 |
2021-07-06 |
Chugai Seiyaku Kabushiki Kaisha |
Method for treating IL-8-related diseases
|
SG10201607778XA
(en)
|
2016-09-16 |
2018-04-27 |
Chugai Pharmaceutical Co Ltd |
Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
|